JenniferAnnKanakryMD

Hematology • Bethesda, MD

Hematologic Oncology

Senior Clinician, National Institutes of Health

Join to view full profile

Dr. Kanakry is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kanakry's full profile

Already have an account?

Office
10 Center Drive
Bethesda, MD 20892

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
Johns Hopkins UniversityResidency, Internal Medicine, 2007 - 2010
Geisel School of Medicine at DartmouthClass of 2007

Certifications & Licensure

MD State Medical License 2010 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors Start of enrollment: 2014 Jul 01
Terminated
Early Phase 1
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies Start of enrollment: 2015 Nov 19
RECRUITING
PHASE2
Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010 Start of enrollment: 2017 Apr 13
COMPLETED
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation Start of enrollment: 2018 Sep 04
ACTIVE_NOT_RECRUITING
PHASE2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma Start of enrollment: 2019 Apr 18
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... Start of enrollment: 2023 Jan 26
RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation.
Rohtesh S Mehta, Hannah Choe, Jennifer Saultz, Zimu Gong, Prashant Sharma
American Journal of Hematology. 2025-03-12
Intermediate-Dose Post-Transplantation Cyclophosphamide for Myeloablative HLA-Haploidentical Bone Marrow Transplantation.
Mustafa A Hyder, Dimana Dimitrova, Ruby Sabina, Ashley DeVries, Jeannine S McCune
Blood Advances. 2025-02-05
Safety but limited efficacy of donor lymphocyte infusion for post-transplantation cyclophosphamide-treated patients.
Krithika Shanmugasundaram, Scott Napier, Dimana Dimitrova, Anita Stokes, Jennifer Wilder
Bone Marrow Transplantation. 2024-11-01

Press Mentions

NCI's First Woman Senior ClinicianJuly 28th, 2022
First In Human DocuseriesJuly 12th, 2015

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/jennifer-kanakry